Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.
Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.
AIM ImmunoTech (NYSE American: AIM) commenced a rights offering distributing non-transferable Subscription Rights to holders of record as of Feb 10, 2026 to purchase up to 12,000 Units at $1,000 per Unit, implying $12.0 million gross proceeds if fully subscribed.
Each Unit includes one share of Series G convertible preferred (convertible into 833 common shares) and 1,666 five-year warrants exercisable at $1.20 per share. Subscription Period runs from Feb 11–27, 2026 (expected expiration 5:00 p.m. ET Feb 27, 2026).
AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell event on Thursday, February 19, 2026 at 4:00 PM ET featuring CEO Thomas K. Equels. The presentation will focus on the lead drug Ampligen and the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer.
A live video webcast will be available on the company Events page, with a replay posted two hours after the live presentation and accessible for 90 days.
AIM ImmunoTech (NYSE American: AIM) has commenced a rights offering to sell up to 12,000 Units at $1,000 per Unit, targeting aggregate gross proceeds of $12.0 million. Each Unit consists of one share of Series G convertible preferred stock and 1,666 warrants.
Each preferred share converts into 833 common shares (conversion price $1.20); each warrant is exercisable for one common share at $1.20 through five years. Subscription rights are non-transferable and expire at 5:00 p.m. ET on February 27, 2026, unless extended.
AIM ImmunoTech (NYSE American: AIM) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually February 10-11, 2026. CEO Thomas K. Equels will present a corporate overview and business outlook with emphasis on AIM's strategic focus on pancreatic cancer.
Presentation details: Wednesday, February 11, 2026 at 1:40 PM EST; registration and current corporate presentation on Ampligen breakthroughs are available.
AIM (NYSE American: AIM) reported a year-end Phase 2 interim update (Feb 5, 2026) for Ampligen (rintatolimod) combined with AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer.
Key points: 18 patients enrolled of up to 25, continuation of promising PFS and OS signals from Phase 1, no significant toxicity reported, patent protection to 2039, and orphan drug designations in US and EU.
AIM ImmunoTech (NYSE American: AIM) amended key dates and terms for its previously announced rights offering. The subscription period is now Feb 11–Feb 27, 2026, and the company expects gross proceeds of $12.0 million if fully subscribed. Subscription Rights are non-transferable and include an over-subscription privilege. Proceeds are intended for clinical trial and manufacturing expenses for prospective Phase 2/3 pancreatic cancer trials and partial repayment of existing debt.
AIM ImmunoTech (NYSE American: AIM) announced a proposed rights offering expected to raise up to $12.0 million if fully subscribed. Record Date is Feb 4, 2026; Subscription Period is Feb 5–Feb 23, 2026. Each holder receives one non-transferable Subscription Right to buy one unit at $1,000 per unit. Each unit consists of one share of Series G Convertible Preferred Stock and warrants to purchase 1,492 shares of common stock.
Preferred shares are convertible at an initial conversion price of $1.34 per share; each warrant exercisable at $1.34 for five years. Over-subscription privileges apply. CEO Thomas K. Equels indicated non-binding intent to participate. Net proceeds intended for clinical/manufacturing expenses and partial debt repayment.
AIM ImmunoTech (NYSE American: AIM) announced a stock dividend of one share for every 1,000 shares of common stock and one share for every outstanding option or warrant entitled to stock dividends.
Record date: January 9, 2026. Distribution/allocation to DTCC: January 13, 2026. Fractional shares will be rounded down; remaining fractional entitlements will be paid in cash based on a per‑share price of $1.305 (average high/low on December 29, 2025). Stockholders need take no action; additional shares will be credited to book‑entry accounts or delivered to brokers. The dividend is administered by EQ, the company's transfer agent.
AIM ImmunoTech (NYSE American: AIM) published a new CEO Corner segment on December 10, 2025. CEO Thomas Equels discusses the unmet need in pancreatic cancer and the company’s lead therapy Ampligen (rintatolimod).
The segment summarizes Ampligen’s ongoing clinical evaluation in the DURIPANC Phase 1b/2 trial where it is being tested in combination with AstraZeneca’s Imfinzi (durvalumab). The CEO Corner video and comments are now available on the company website.
AIM ImmunoTech (NYSE American: AIM) CEO Thomas K. Equels will appear in a live, moderated "fireside" chat on the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. The discussion will focus on AIM's clinical and regulatory strategy for lead drug Ampligen, including the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer.
Equels will also review a completed Phase 2 trial with Merck evaluating Ampligen plus Keytruda (pembrolizumab) in advanced recurrent ovarian cancer; an abstract was presented at the 40th Annual SITC Meeting. Interested parties can submit questions in advance to aim@jtcir.com. A live webcast will stream on the company's Events page and a replay will be available two hours after the live presentation for 90 days.